ArticleInternational journal of clinical pharmacology and therapeutics2010
Atorvastatin-induced acute elevation of hepatic enzymes and the absence of cross-toxicity of pravastatin.
Article in International journal of clinical pharmacology and therapeutics, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 32 citations in OpenAlex.
- Patients on statins with elevated transaminases: Frequency of follow-up creatine kinase testing and gastroenterology referral.British journal of clinical pharmacology · 2026Article
- A hierarchical risk assessment framework for head-to-head comparison of statin safety profiles in Chinese patients.Scientific reports · 2026Article
- Atorvastatin-Associated Liver Injury: Outcome After Statin Rechallenge.Fundamental & clinical pharmacology · 2026Article
- IQ DILI Consensus Opinion: Best Practices for Rechallenge Following Suspected Drug-Induced Liver Injury in Clinical Trials.Drug safety · 2025Article
- Statin-induced Liver Injury Patterns: A Clinical Review.Journal of clinical and translational hepatology · 2022Review
- Evaluation of Patient's Knowledge of Atorvastatin Information in Patient Information Leaflets: A Pre-Post Intervention Study in Thailand.Patient preference and adherence · 2021Article
- Effective atherosclerotic plaque inflammation inhibition with targeted drug delivery by hyaluronan conjugated atorvastatin nanoparticles.Nanoscale · 2020Article
- Article
- Hepatoprotective Effects of a Novel Trihoney against Nonalcoholic Fatty Liver Disease: A Comparative Study with Atorvastatin.TheScientificWorldJournal · 2020Article
- Cholangiolytic Changes in Statin-Induced Liver Injury.Case reports in pathology · 2020Article
- ABCB1 polymorphism is associated with atorvastatin-induced liver injury in Japanese population.BMC genetics · 2016Article
- Multi-Organ toxicity demonstration in a functional human in vitro system composed of four organs.Scientific reports · 2016Article
- Bioenergetic study of murine hepatic tissue treated in vitro with atorvastatin.BMC pharmacology & toxicology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
Atorvastatin has been associated with liver injury. We reported here two cases of aminotransferases elevation within 12 h of low-dose atorvastatin therapy. Liver functions were fully recovered to the baseline level 11 days after discontinuation of atorvastatin treatment. The possible relative risk factors included advanced age, chronic and systemic diseases, and co-administration of cytochrome P450 3A (CYP3A) enzyme-dependent metabolic drugs or its inhibitors such as clopidogrel and diltiazem. No significant transaminase elevation was observed after switching to pravastatin. Thus, pravastatin might be safer than atorvastain in patients with chronic or systemic diseases, or with co-administration of CYP3A enzyme-dependent drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.